IST et PrEp

DOI:10.1097/QAD.0000000000001185 AIDS2016,30:2251 – 2252 2251 In March 2016, we conducted a literature review with the MeSHterms ‘SYPHILIS’ OR ‘GONORRHEA’ OR ‘CHLAMYDIA’ OR ‘HOMOSEXUALITY’ OR ‘MALE’ OR ‘TRANSGENDER PERSONS’ AND ‘COHORT STUDIES’ usingPubMedas a search platform. We identified over 140000 studies, including all five studies on PrEP (Supplemental Table; http://links.lww. com/QAD/ A944). We restricted studies to only those with the following inclusion criteria: English language, cohort of MSM, and STI incidence rates reported with nucleic acid amplification testing. We conducted a metaanalysis of those studies to compare incidence rate ratios of STIs between MSM using PrEP versus MSM not using PrEP. Our results, as well as prior studies, support updating Center for Disease Control and Prevention guidelines to recommend that MSM using PrEP receive quarterly STI screenings, an increase from their current guidelines that recommend biannual to quarterly screenings [7,8]. Furthermore, physicians must not only vigilantly identify patients that may benefit from PrEP but also provide their patients with a sexual health prevention package that includes quarterly STI screenings, timely treatment of We conducted a meta-analysis to summarize rates of sexually transmitted infections among men who have sex with men (MSM) on pre-exposure prophylaxis (PrEP) for HIV versus MSM not using PrEP. Incidence rate ratios showed that MSM using PrEP were 25.